Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evolution of metastatic colorectal cancer

ABSTRACT: An in-depth examination of genomic heterogeneity of disseminated colorectal cancer: a post mortem study

PROVIDER: PRJEB14293 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Streptococcus oralis subsp. tigurinus strain:osk_001

Project description:Microbiological diagnosis by post-mortem examination

| PRJDB5718 | ENA

Dissecting the Epithelial and Immune Evolution during Colorectal Carcinogenesis by Single-Cell RNA Sequencing

Project description:Adenoma-carcinoma sequence is a well-accepted roadmap for the development of sporadic colorectal carcinoma. However, cellular heterogeneity in aberrant epithelia and the complexity of tumor microenvironment limited the understanding of carcinogenesis. Here we performed a scRNA-seq survey from patient-matched samples, including blood, normal, para-cancer, polyp, and cancer tissues.

2021-12-30 | GSE161277 | GEO

Proteomic characterization of metastatic colorectal cancer

Project description:To characterize metastatic progression of colorectal cancer, we performed mass spectrometry-based proteome analysis using large clinical cohort samples.

2024-01-16 | PXD031705 | Pride

microRNA data in human metastatic versus non-metastatic colorectal cancer tissues

Project description:This study was to identify microRNAs responsible for colorectal cancer

2017-08-15 | GSE93377 | GEO

hepatic metastatic colorectal cancer gene expression array

Project description:The goal of this experiment was to build gene expression signature associated with long-term outcomes of patients with hepatic metastatic colorectal cancer. The samples were corrected from surgically resected liver metastasis and extracted RNA was subjected to Illumina expression gene chip analysis.

2014-01-14 | E-MTAB-1951 | biostudies-arrayexpress

Characterization of spatial heterogeneity in metastasized colorectal cancer by MALDI imaging

Project description:About 50% of colorectal cancer patients develop liver metastases. Patients with metastatic colorectal cancer have 5-year survival rates below 20% despite new therapeutic regimens. Tumor heterogeneity has been linked with poor clinical outcome, but was so far mainly studied via bulk genomic analyses. In this study we performed spatial proteomics via MALDI mass spectrometry imaging on six patient matched CRC primary tumor and liver metastases to characterize interpatient, intertumor and intratumor hetereogeneity. We found several peptide features that were enriched in vital tumor areas of primary tumors and liver metastasis and tentatively derived from tumor cell specific proteins such as annexin A4 and prelamin A/C. Liver metastases of colorectal cancer showed higher heterogeneity between patients than primary tumors while within patients both entities show similar intratumor heterogeneity sometimes organized in zonal pattern. Together our findings give new insights into the spatial proteomic heterogeneity of primary CRC and patient matched liver metastases.

2023-02-17 | PXD039409 | Pride

RNAseq analysis on metastatic Colorectal Cancer

Project description:RNAseq analysis on metastatic Colorectal Cancer

| PRJNA842377 | ENA

The clonal evolution of metastatic colorectal cancer.

Project description:Tumor heterogeneity and evolution drive treatment resistance in metastatic colorectal cancer (mCRC). Patient-derived xenografts (PDXs) can model mCRC biology; however, their ability to accurately mimic human tumor heterogeneity is unclear. Current genomic studies in mCRC have limited scope and lack matched PDXs. Therefore, the landscape of tumor heterogeneity and its impact on the evolution of metastasis and PDXs remain undefined. We performed whole-genome, deep exome, and targeted validation sequencing of multiple primary regions, matched distant metastases, and PDXs from 11 patients with mCRC. We observed intricate clonal heterogeneity and evolution affecting metastasis dissemination and PDX clonal selection. Metastasis formation followed both monoclonal and polyclonal seeding models. In four cases, metastasis-seeding clones were not identified in any primary region, consistent with a metastasis-seeding-metastasis model. PDXs underrepresented the subclonal heterogeneity of parental tumors. These suggest that single sample tumor sequencing and current PDX models may be insufficient to guide precision medicine.

| S-EPMC7286679 | biostudies-literature

Genomic landscape of metastatic colorectal cancer

Project description:Response to drug therapy in individual colorectal cancer (CRC) patients is associated with tumor biology. Here we describe the genomic landscape of tumor samples of a homogeneous well-annotated series of patients with metastatic CRC of two phase III clinical trials, CAIRO and CAIRO2. DNA copy number aberrations of 349 patients are determined. Within three treatment arms, 194 chromosomal sub-regions are associated with progression free survival PFS (uncorrected single-test p-values < 0.005). These sub-regions are filtered for effect on mRNA expression, using an independent data set from The Cancer Genome Atlas (TCGA) which returned 171 genes. Three chromosomal regions are associated with a significant difference in PFS between treatment arms with or without irinotecan. One of these regions, 6q16.1-q21, correlates in vitro with sensitivity to SN-38, the active metabolite of irinotecan. This genomic landscape of metastatic CRC reveals a number of DNA copy number aberrations associated with response to drug therapy. aCGH data of colorectal cancers of patients from 2 clinical trials (CAIRO, CAIRO2). 105 patients were treated with capecitabine first line (CAIRO arm A), 111 patients were treated with capecitabine and irinotecan first line (CAIRO arm B), and 133 patients were treated with capecitabine, oxaliplatin and bevacizumab (CAIRO2 arm A).

2014-11-14 | E-GEOD-36864 | biostudies-arrayexpress

Expression changes of ecDNA in colorectal epithelium-adenoma-adenocarcinoma evolution (mRNA)

Project description:We collected 5 normal colon tissues, 5 colorectal adenomas, and 5 colorectal cancer tissues for high-throughput sequencing. Identify differential expression changes in mRNA during disease progression

2024-11-27 | GSE226739 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data